MedTrace Logo

A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects

NCT04208152 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2020-08-06

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

anle138b

capsule containing excipient and anle138b

DRUG

Placebo

matching placebo capsule containing excipient

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Aptuit

    collaborator INDUSTRY

  • MODAG GmbH

    lead INDUSTRY

Principal Investigators

  • Nand Singh, BSc, MD, DPM, MFPM · Quotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-06
Primary Completion
2020-08-04
Completion
2020-08-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208152 on ClinicalTrials.gov